Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of Sativex for spasticity in motor neuron disease
2010-022808-40Phase 2Completed
- Sponsor
- Fondazione Centro San Raffaele
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in motor neuron disease (MND), amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS) comparing Sativex with Placebo (2 arms). Primary endpoint: Modified Ashworth Scale score. Started Feb 2011; status: completed.
02
Drugs
cannabidiol
03
Conditions
motor neuron disease (MND)amyotrophic lateral sclerosis (ALS)primary lateral sclerosis (PLS)
Beyond the preview
Go deeper on 2010-022808-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022808-40.